Paclitaxel as second-line chemotherapy in patients with gemcitabine-refractory pancreatic cancer: A retrospective study

International Journal of Clinical Oncology

Volumn 16, Issue 5, 2011, Pages 539-545

  Maeda, Shimpei ^a   Motoi, Fuyuhiko ^a   Onogawa, Tohru ^a   Morikawa, Takanori ^a   Shigeru, Ottomo ^a   Sakata, Naoaki ^a   Takadate, Tatsuyuki ^a   Naitoh, Takeshi ^a   Rikiyama, Toshiki ^a   Katayose, Yu ^a   Egawa, Shinichi ^a   Unno, Michiaki ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Gemcitabine; Paclitaxel; Pancreatic cancer; Second line chemotherapy

Indexed keywords

AZASETRON; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CISPLATIN; DEXAMETHASONE; DIPHENHYDRAMINE; DUPAN 2; FAMOTIDINE; FLUOROURACIL; GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; PACLITAXEL; TUMOR MARKER; UFT; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; DU PAN 2 ANTIGEN, HUMAN; DU-PAN-2 ANTIGEN, HUMAN; PHARMACOLOGICAL BIOMARKER; TUMOR ANTIGEN;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER CONTROL; CLINICAL ARTICLE; CONSERVATIVE TREATMENT; CORRELATION ANALYSIS; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HISTOPATHOLOGY; HUMAN; INTERSTITIAL PNEUMONIA; LEUKOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROPATHY; OVERALL SURVIVAL; PANCREAS CANCER; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SALVAGE THERAPY; SIDE EFFECT; STOMATITIS; SURVIVAL TIME; TASTE DISORDER; THROMBOCYTOPENIA; CANCER STAGING; METABOLISM; MIDDLE AGED; PANCREAS TUMOR; PATHOLOGY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOMARKERS, PHARMACOLOGICAL; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; DEOXYCYTIDINE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; PANCREATIC NEOPLASMS; RETROSPECTIVE STUDIES; SALVAGE THERAPY;

EID: 84857088330     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-011-0220-8     Document Type: Article

References (28)

1. Jemal A, Siegel R, Ward E et al (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225-249
2. Matsuda T, Marugame T, Kamo K et al (2009) Cancer incidence and incidence rates in Japan in 2003: based on data from 13 population-based cancer registries in the Monitoring of Cancer Incidence in Japan (MCIJ) Project. Jpn J Clin Oncol 39:850-858
3. Burris HA 3rd, Moore MJ, Andersen J et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403-2413 (Pubitemid 27251144)
4. Matsuno S, Egawa S, Fukuyama S et al (2004) Pancreatic Cancer Registry in Japan: 20 years of experience. Pancreas 28:219-230 (Pubitemid 38437313)
5. Ueno H, Kosuge T, Matsuyama Y et al (2009) A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br J Cancer 101:908-915
6. Pelzer U, Kubica K, Stieler J et al (2008) A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study. J Clin Oncol 26:217 (abstract 4508)
7. Rowinsky EK (1997) The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu Rev Med 48:353-374 (Pubitemid 27101837)
8. Oettle H, Arnold D, Esser M et al (2000) Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma. Anticancer Drugs 11:635-638
9. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
10. Burris HA 3rd (2005) Recent updates on the role of chemotherapy in pancreatic cancer. Semin Oncol 32:S1-S3 (Pubitemid 41242644)
11. Kim YJ, Bang S, Park JY et al (2009) Phase II study of 5-fluorouracil and paclitaxel in patients with gemcitabine-refractory pancreatic cancer. Cancer Chemother Pharmacol 63:529-533
12. Nakachi K, Furuse J, Ishii H et al (2007) Prognostic factors in patients with gemcitabine-refractory pancreatic cancer. Jpn J Clin Oncol 37:114-120 (Pubitemid 47090708)
13. Ikeda M, Okada S, Tokuuye K et al (2001) Prognostic factors in patients with locally advanced pancreatic carcinoma receiving chemoradiotherapy. Cancer 91:490-495 (Pubitemid 32105694)
14. Krishnan S, Rana V, Janjan NA et al (2006) Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation. Cancer 107:2589-2596 (Pubitemid 44845612)
15. Ueno H, Okada S, Okusaka T et al (2000) Prognostic factors in patients with metastatic pancreatic adenocarcinoma receiving systemic chemotherapy. Oncology 59:296-301
16. Ko AH, Hwang J, Venook AP et al (2005) Serum CA 19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. Br J Cancer 93:195-199 (Pubitemid 41133205)
17. Stemmler J, Stieber P, Szymala AM et al (2003) Are serial CA 19-9 kinetics helpful in predicting survival in patients with advanced or metastatic pancreatic cancer treated with gemcitabine and cisplatin? Onkologie 26:462-467 (Pubitemid 37409891)
18. Wong D, Ko AH, Hwang J et al (2008) Serum CA 19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapy. Pancreas 37:269-274
19. Halm U, Schumann T, Schiefke I et al (2000) Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer. Br J Cancer 82:1013-1016 (Pubitemid 30128852)
20. Ziske C, Schlie C, Gorschluter M et al (2003) Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine. Br J Cancer 89:1413-1417 (Pubitemid 37386593)
21. Maisey NR, Norman AR, Hill A et al (2005) CA 19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials. Br J Cancer 93:740-743 (Pubitemid 41486431)
22. Berlin JD, Catalano P, Thomas JP et al (2002) Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 20: 3270-3275 (Pubitemid 34831525)
23. Louvet C, Labianca R, Hammel P et al (2005) Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 23:3509-3516
24. Poplin E, Feng Y, Berlin J et al (2009) Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 27:3778-3785
25. Agheli A, Park SC, Huang CJ et al (2009) Apparent beneficial effects by nab-paclitaxel in the treatment of refractory metastatic ovarian carcinoma. Anticancer Drugs 20:525-526
26. Gradishar WJ, Krasnojon D, Cheporov S et al (2009) Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol 27:3611-3619
27. Rizvi NA, Riely GJ, Azzoli CG et al (2008) Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer. J Clin Oncol 26:639-643 (Pubitemid 351264360)
28. Robinson DM, Keating GM (2006) Albumin-bound paclitaxel: in metastatic breast cancer. Drugs 66:941-948 (Pubitemid 43847372)